Free Trial
NASDAQ:TRAW

Traws Pharma (TRAW) Stock Price, News & Analysis

Traws Pharma logo
$4.99
-0.05 (-0.99%)
(As of 11/1/2024 ET)

About Traws Pharma Stock (NASDAQ:TRAW)

Key Stats

Today's Range
$4.92
$5.17
50-Day Range
N/A
52-Week Range
$4.44
$27.50
Volume
2,606 shs
Average Volume
11,322 shs
Market Capitalization
$9.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Traws Pharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
34th Percentile Overall Score

TRAW MarketRank™: 

Traws Pharma scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Traws Pharma are expected to grow in the coming year, from ($146.00) to ($33.75) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Traws Pharma is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Traws Pharma is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Traws Pharma has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Traws Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    0.32% of the float of Traws Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Traws Pharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Traws Pharma has recently decreased by 24.22%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Traws Pharma does not currently pay a dividend.

  • Dividend Growth

    Traws Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.32% of the float of Traws Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Traws Pharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Traws Pharma has recently decreased by 24.22%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Traws Pharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.
  • MarketBeat Follows

    Only 1 people have added Traws Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Traws Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.10% of the stock of Traws Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.95% of the stock of Traws Pharma is held by institutions.

  • Read more about Traws Pharma's insider trading history.
Receive TRAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Traws Pharma and its competitors with MarketBeat's FREE daily newsletter.

TRAW Stock News Headlines

We recommended Nvidia in 2016, now we’re recommending this…
The AI boom is just getting started. And the real wealth has still to be made…
Why Traws Pharma Is Rising In Pre-market?
See More Headlines

TRAW Stock Analysis - Frequently Asked Questions

Traws Pharma's stock was trading at $7.50 at the start of the year. Since then, TRAW stock has decreased by 33.5% and is now trading at $4.9908.
View the best growth stocks for 2024 here
.

Traws Pharma, Inc. (NASDAQ:TRAW) released its earnings results on Thursday, August, 15th. The company reported ($4.87) earnings per share (EPS) for the quarter. The business had revenue of $0.06 million for the quarter. Traws Pharma had a negative trailing twelve-month return on equity of 144.95% and a negative net margin of 60,641.14%.

Shares of TRAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Traws Pharma investors own include Clearside Biomedical (CLSD), Evofem Biosciences (EVFM), Nikola (NKLA), Palatin Technologies (PTN), Sirius XM (SIRI), Adverum Biotechnologies (ADVM) and Aptinyx (APTX).

Company Calendar

Last Earnings
8/15/2024
Today
11/02/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TRAW
Previous Symbol
NASDAQ:TRAW
Employees
17
Year Founded
N/A

Profitability

Net Income
$-18,950,000.00
Net Margins
-60,641.14%
Pretax Margin
-60,641.14%

Debt

Sales & Book Value

Annual Sales
$226,000.00
Book Value
$12.70 per share

Miscellaneous

Free Float
1,533,000
Market Cap
$9.12 million
Optionable
Optionable
Beta
1.37
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:TRAW) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners